Moleculin Biotech
MBRX | NASDAQ
$7.14
-$0.73 (-9.28%)
At close: Nov 16, 2026, 4:00 PM ET
$7.46
+$0.32 (+4.48%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Moleculin Biotech Company Profile
Company profile explainedCompany Profile
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Key Executives
| Name | Position |
|---|---|
| Walter V. Klemp | Chairman, President & CEO |
| Jonathan Foster | Executive Vice President & Chief Financial Officer |
| Donald H. Picker | Chief Scientific Officer |
| John Paul Waymack | Senior Chief Medical Officer |
| Waldemar Priebe | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 8-K | Current Report |
| Oct 20, 2026 | 8-K | Current Report |
| Oct 16, 2026 | 4 | Filing |
| Oct 16, 2026 | 4 | Filing |
| Oct 16, 2026 | 4 | Filing |
| Oct 16, 2026 | 8-K | Current Report |
| Oct 15, 2026 | S-8 | Filing |
| Oct 09, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 8-K | Current Report |
| Sep 29, 2026 | 8-K | Current Report |
Moleculin Biotech
| Country | United States |
| IPO Date | Jun 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Walter V. Klemp |
Contact Details
5300 Memorial Drive Houston,
Texas 77007 United States
Stock Details
| Ticker Symbol | MBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659617 |
| CUSIP Number | 60855D507 |
| ISIN Number | US60855D5077 |
| SIC Code | 2834 |
Recent News
- 28 days ago / globenewswire.comMoleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
- 1 month ago / globenewswire.comMoleculin Announces Reverse Stock Split
- 1 month ago / globenewswire.comMoleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
- 2 months ago / globenewswire.comMoleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
- 2 months ago / globenewswire.comMoleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
- 2 months ago / globenewswire.comAnnamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
- 2 months ago / globenewswire.comMoleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
- 2 months ago / globenewswire.comMoleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
- 2 months ago / globenewswire.comMoleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
Add to Watchlist
Select watchlists to add or remove MBRX